Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Urology
Volume 2014 (2014), Article ID 871481, 2 pages
http://dx.doi.org/10.1155/2014/871481
Case Report

Dabigatran Induced Hemorrhagic Cystitis in a Patient with Painful Bladder Syndrome

1Department of Obstetrics and Gynecology, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37604, USA
2Intermountain Budge OB/GYN Clinic, Logan Regional Hospital, Logan, UT 84341, USA

Received 6 December 2013; Accepted 25 December 2013; Published 13 March 2014

Academic Editors: R. Chesson, P. H. Chiang, and B. K. Malhotra

Copyright © 2014 Helen Otteno et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Product Information: PRADAXA(R) Oral Capsules, Dabigatran Etexilate Mesylate Oral Capsules, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn, USA, 2011.
  2. B. I. Eriksson and R. Friedman, “Dabigatran exilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty,” Clinical and Applied Thrombosis/Hemostasis, vol. 15, supplement 1, pp. 25S–31S, 2009. View at Publisher · View at Google Scholar
  3. S. J. Connolly, M. D. Ezekowitz, S. Yusuf et al., “Dabigatran versus warfarin in patients with atrial fibrillation,” The New England Journal of Medicine, vol. 361, pp. 1139–1151, 2009. View at Publisher · View at Google Scholar
  4. V. Katz, G. Lentz, R. Lobo, and D. Gershenson, “Urogynecology,” in Comprehensive Gynecology, chapter 21, pp. 547–549, Elsevier, 2007. View at Google Scholar